Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic
The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy i...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/8/819 |
| _version_ | 1827684362273947648 |
|---|---|
| author | José M. Serra López-Matencio Manuel Gómez Esther F. Vicente-Rabaneda Miguel A. González-Gay Julio Ancochea Santos Castañeda |
| author_facet | José M. Serra López-Matencio Manuel Gómez Esther F. Vicente-Rabaneda Miguel A. González-Gay Julio Ancochea Santos Castañeda |
| author_sort | José M. Serra López-Matencio |
| collection | DOAJ |
| description | The discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy in reducing disease advancement. However, the goal of completely halting disease progress has not been reached yet. Administering nintedanib with add-on pirfenidone is supposed to enhance the therapeutic benefit by simultaneously acting on two different pathogenic pathways. All this becomes more important in the context of the ongoing global pandemic of coronavirus disease 2019 (COVID-19) because of the fibrotic consequences following SARS-CoV-2 infection in some patients. However, little information is available about their drug–drug interaction, which is important mainly in polymedicated patients. The aim of this review is to describe the current management of progressive fibrosing interstitial lung diseases (PF-ILDs) in general and of IPF in particular, focusing on the pharmacokinetic drug-drug interactions between these two drugs and their relationship with other medications in patients with IPF. |
| first_indexed | 2024-03-10T08:29:12Z |
| format | Article |
| id | doaj.art-5693485fefc14c169a0c2dc41a6c98b4 |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-10T08:29:12Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-5693485fefc14c169a0c2dc41a6c98b42023-11-22T09:12:19ZengMDPI AGPharmaceuticals1424-82472021-08-0114881910.3390/ph14080819Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 PandemicJosé M. Serra López-Matencio0Manuel Gómez1Esther F. Vicente-Rabaneda2Miguel A. González-Gay3Julio Ancochea4Santos Castañeda5Hospital Pharmacy Service, Princesa Hospital, IIS-Princesa, c/Diego de León 62, 28006 Madrid, SpainMethodology Unit, Health Research Institute Princesa (IIS-IP), c/Diego de León 62, 28006 Madrid, SpainRheumatology Service, Princesa Hospital, IIS-Princesa, c/Diego de León 62, 28006 Madrid, SpainRheumatology Service, Marqués de Valdecilla Universitary Hospital, University of Cantabria, Av. de Valdecilla 25, 39008 Santander, SpainPneumology Service, Princesa Hospital, Autonomous University of Madrid (UAM), IIS-Princesa, c/Diego de León 62, 28006 Madrid, SpainRheumatology Service, Princesa Hospital, IIS-Princesa, c/Diego de León 62, 28006 Madrid, SpainThe discovery of antifibrotic agents have resulted in advances in the therapeutic management of idiopathic pulmonary fibrosis (IPF). Currently, nintedanib and pirfenidone have become the basis of IPF therapy based on the results of large randomized clinical trials showing their safety and efficacy in reducing disease advancement. However, the goal of completely halting disease progress has not been reached yet. Administering nintedanib with add-on pirfenidone is supposed to enhance the therapeutic benefit by simultaneously acting on two different pathogenic pathways. All this becomes more important in the context of the ongoing global pandemic of coronavirus disease 2019 (COVID-19) because of the fibrotic consequences following SARS-CoV-2 infection in some patients. However, little information is available about their drug–drug interaction, which is important mainly in polymedicated patients. The aim of this review is to describe the current management of progressive fibrosing interstitial lung diseases (PF-ILDs) in general and of IPF in particular, focusing on the pharmacokinetic drug-drug interactions between these two drugs and their relationship with other medications in patients with IPF.https://www.mdpi.com/1424-8247/14/8/819antifibrotic agentsCOVID-19interstitial lung diseaseIPFprogressive fibrosing ILDUIP |
| spellingShingle | José M. Serra López-Matencio Manuel Gómez Esther F. Vicente-Rabaneda Miguel A. González-Gay Julio Ancochea Santos Castañeda Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic Pharmaceuticals antifibrotic agents COVID-19 interstitial lung disease IPF progressive fibrosing ILD UIP |
| title | Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic |
| title_full | Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic |
| title_fullStr | Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic |
| title_full_unstemmed | Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic |
| title_short | Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic |
| title_sort | pharmacological interactions of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis in times of covid 19 pandemic |
| topic | antifibrotic agents COVID-19 interstitial lung disease IPF progressive fibrosing ILD UIP |
| url | https://www.mdpi.com/1424-8247/14/8/819 |
| work_keys_str_mv | AT josemserralopezmatencio pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic AT manuelgomez pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic AT estherfvicenterabaneda pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic AT miguelagonzalezgay pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic AT julioancochea pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic AT santoscastaneda pharmacologicalinteractionsofnintedanibandpirfenidoneinpatientswithidiopathicpulmonaryfibrosisintimesofcovid19pandemic |